HALO logo
halo search icon
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
ABUS · NAS

Arbutus Biopharma Corporation

US$4.37

Price Arrow0.17 (4.05%)
20/05/2026 04:00:01 PM
All-CompaniesAll-ConsensusEMA 125 BreakdownFakey Shakey - LongFakey Shakey - Long (Realtime)HALO AllHALO Earnings MomentumHALO Growth+2
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Arbutus Biopharma Corporation Overview

ABUS Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About ABUS

icon

Telephone

1.267.469.0914

icon

Address

701 Veterans Circle, Warminster, PA 18974

Description

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

ABUS Price Chart

Key Stats

Market Cap

US$829.66M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 3.04 - 5.1

Trade Value (12mth)

US$1,492,938.00

1 week

-0.94%

1 month

-5.19%

YTD

-11.95%

1 year

32.49%

All time high

31.48

Key Fundamentals

EPS 3 yr Growth

-62.00%

EBITDA Margin

-189.50%

Operating Cashflow

-$40m

Free Cash Flow Return

-43.30%

ROIC

-36.60%

Interest Coverage

-275.10

Quick Ratio

15.70

Other Data

Shares Outstanding (Fully Diluted)

195m

HALO Sector

Healthcare

Next Company Report Date

04-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

ABUS Announcements

Latest Announcements

DateAnnouncements
13 May 26
13 May 26
13 May 26
15 April 26
23 March 26

ABUS Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-0.44-0.38-0.17locklocklock
EPS (Fully Diluted)
$locklocklocklock-0.44-0.38-0.17locklocklock
Growth
%locklocklocklock4.614.253.6locklocklock
PE
XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Arbutus Biopharma Corporation (ABUS:NAS)?
Halo FAQ
The current share price of Arbutus Biopharma Corporation (ABUS:NAS) is USD$4.37.
What is the 52-week high share price for Arbutus Biopharma Corporation (ABUS:NAS)?
Halo FAQ
The 52-week high share price for Arbutus Biopharma Corporation (ABUS:NAS) is USD$5.10.
What is the 52-week low share price for Arbutus Biopharma Corporation (ABUS:NAS)?
Halo FAQ
The 52-week low share price for Arbutus Biopharma Corporation (ABUS:NAS) is USD$3.04.
What is the dividend yield for Arbutus Biopharma Corporation (ABUS:NAS)?
Halo FAQ
Arbutus Biopharma Corporation (ABUS:NAS) does not pay a dividend.
What was Arbutus Biopharma Corporation (ABUS:NAS) last dividend payment?
Halo FAQ
Arbutus Biopharma Corporation (ABUS:NAS) does not pay a dividend.
What is the franking level for Arbutus Biopharma Corporation (ABUS:NAS)?
Halo FAQ
Arbutus Biopharma Corporation (ABUS:NAS) has a franking level of 0.00%.
In which sector is Arbutus Biopharma Corporation (ABUS:NAS) classified?
Halo FAQ
Arbutus Biopharma Corporation (ABUS:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.